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Penal Insufficiency as an Independent Predictor
f Mortality Among Women With Heart Failure
irsten Bibbins-Domingo, PHD, MD,*† Feng Lin, MS,† Eric Vittinghoff, PHD,†
lizabeth Barrett-Connor, MD,‡ Deborah Grady, MD, MPH,†§ Michael G. Shlipak, MD, MPH†§
an Francisco and San Diego, California
OBJECTIVES We sought to explore the association between renal insufficiency and mortality among women
with heart failure (HF) and to evaluate this risk by the presence of preserved or depressed
systolic function.
BACKGROUND Although HF is common in older women, little is known about their risk factors for
mortality.
METHODS This prospective cohort study retrospectively analyzed data from the Heart and Estrogen/
progestin Replacement Study (HERS). Of the 2,763 women in HERS, 702 had HF. Renal
function was categorized as creatinine clearance (CrCl) 60 ml/min, 40 to 60 ml/min, and
40 ml/min. We used proportional hazards models to evaluate the association between renal
insufficiency and mortality.
RESULTS Over a mean 5.8 years, 228 women with HF died (32%). Renal insufficiency was strongly
associated with mortality, even after adjustment for co-morbid conditions, systolic function,
and medications (adjusted hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.09 to 2.16
for CrCl 40 to 60 ml/min; adjusted HR 2.40, 95% CI 1.60 to 3.62 for CrCl 40 ml/min).
Preserved or depressed systolic function did not modify the association between renal
insufficiency and mortality risk, but the use of angiotensin-converting enzyme (ACE)
inhibitors did modify this risk (ACE users: adjusted HR  0.9, 95% CI 0.6 to 1.6; ACE
nonusers: adjusted HR 2.1, 95% CI 1.3 to 3.2; p  0.02 for interaction). Compared with
other risk factors for mortality, renal insufficiency had the highest population attributable risk
(27%).
CONCLUSIONS Renal insufficiency was a major predictor of mortality among women with HF and preserved
or depressed systolic function. This risk was attenuated by the use of ACE inhibitors. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.040Coll Cardiol 2004;44:1593–600) © 2004 by the American College of Cardiology Foundation
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weart failure (HF) is common among older women and is
ssociated with a high rate of mortality (1,2). However, little
s known about the prognostic factors associated with
ortality among women with HF, partly because of the
mall numbers of women included in HF clinical trials (3).
In studies that included primarily men, end-stage renal
isease was associated with high rates of mortality among
ndividuals with HF (4), and even moderate degrees of renal
nsufficiency may increase the risk of death (5–11). Assess-
ng the independent association between renal insufficiency
nd mortality in HF is challenging, however, because renal
nsufficiency is associated with higher rates of other cardio-
ascular risk factors, such as diabetes and hypertension,
hich may explain the elevated mortality risk.
The association between mild to moderate renal insuffi-
iency and mortality among women with HF has not been
nvestigated. Women with HF are known to have higher
ates of diabetes and hypertension than do men with HF
12), potentially accounting for any association between
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Manuscript received June 3, 2004; revised manuscript received June 29, 2004,
ccepted July 16, 2004.enal insufficiency and mortality in this population. Addi-
ionally, women are known to have higher rates of HF with
reserved systolic function than do men (13,14), and an
ssociation between renal insufficiency and mortality has not
een as well studied for this type of HF.
To determine whether renal insufficiency is a predictor of
ortality in women with HF, we used data from women
ith HF who were participants in the Heart and Estrogen/
rogestin Replacement Study (HERS), a randomized, con-
rolled trial of the effects of hormone therapy on cardiovas-
ular outcomes among women with established coronary
isease.
ETHODS
he HERS methods and main findings have been described
15,16). Briefly, participants were postmenopausal women
ith known coronary disease, as defined by a previous
yocardial infarction, coronary artery bypass graft surgery,
ercutaneous transluminal coronary angioplasty, or angio-
raphic evidence of 50% narrowing of one or more major
oronary arteries. Women were excluded if they were older
han 79 years of age, used hormones within three months,
r had a previous hysterectomy, a coronary event within the
ix months before randomization, serum triglyceride levels
3.39 mmol/l (300 mg/dl), or a history of conditions that
ould contraindicate estrogen therapy (16). Participants
ere randomly assigned within clinical centers to 0.625 mg
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esterone acetate in one tablet daily (n 1,380) or a placebo
f identical appearance (n  1,383). The institutional
eview boards at the coordinating center and each of the 20
ERS clinical centers approved the protocol, and all
articipants provided written, informed consent.
The HERS randomized, controlled trial was conducted
ver 4.1 years. After the conclusion of the trial, women were
nblinded to treatment assignment and were observed for
n additional 2.7 years, on average (HERS-II) (17). Sus-
ected outcome events were either reported by participants
o the clinical center staff or were identified via participant
nterviews that were conducted every four months. Records
f all hospitalizations were reviewed by an independent
orbidity and mortality subcommittee that adjudicated all
uspected outcome events, including hospitalizations for
F. Attributing an admission to HF was made on the basis
f the judgment of these adjudicators, who considered
ultiple factors (clinical presentation, radiographic find-
ngs, physician diagnosis, and treatment). A hospitalization
as attributed to HF if one or more of the following criteria
ere present in the medical record: signs and symptoms of
F, chest x-ray consistent with pulmonary edema, or
reatment with intravenous diuretics.
At the baseline interview, participants provided a self-
eport of their medical history. On baseline physical exam-
nation, a physician assessed signs (jugular venous disten-
ion, third heart sound, significant murmurs, pulmonary
ales, and peripheral edema) and symptoms (New York
eart Association [NYHA] functional classification) of
F. Women with NYHA functional class IV at the
aseline interview were excluded from HERS.
Of the 2,763 women enrolled in the HERS trial, we
xcluded 29 who had a body mass index 18.5 kg/m2. The
ERS participants were included in this analysis if they had
ither a history of HF in their medical history or baseline
nterview (n  343) or developed HF during the HERS or
ERS-II follow-up period, as defined by signs and symp-
oms of HF on an annual visit or hospitalization for HF (n
359). Participants were included in this analysis and
ontributed to follow-up data only after they met one of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
CrCl  creatinine clearance
ECG  electrocardiogram/electrocardiographic
HERS  Heart and Estrogen/progestin Replacement
Study
HF  heart failure
HR  hazard ratio
LVEF  left ventricular ejection fraction
NYHA  New York Heart Associationhese eligibility criteria. iotential predictors of mortality. Creatinine was mea-
ured from serum samples, and body mass index was
alculated from height and weight measured at baseline.
hese were used to estimate creatinine clearance (CrCl)
sing the Cockcroft-Gault equation (18). Renal function
as categorized based on estimated CrCl: 60 ml/min, 40
o 60 ml/min, and 40 ml/min. These categories were
odified from the National Kidney Foundation cutpoints
f60 ml/min, 30 to 60 ml/min, and30 ml/min, because
ew HERS participants had CrCl 30 ml/min (19).
Demographic characteristics, behavioral risk factors,
edical history, and medication use were determined by
articipant self-reporting on enrollment in HERS. Left
entricular hypertrophy was determined from the baseline
lectrocardiogram (ECG). Fasting levels of high-density
ipoprotein cholesterol, lipoprotein(a), and triglycerides
ere measured by a central laboratory, and low-density
ipoprotein cholesterol levels were calculated using the
riedewald equation (20).
Left ventricular ejection fraction (LVEF), determined
rom a chart review at baseline, was used to classify
articipants as having preserved systolic function (LVEF
50%) and depressed systolic function (LVEF 50%).
ecause echocardiography was not a required test in HERS,
VEF was unavailable in 230 of the 702 participants in this
nalysis.
Systolic blood pressure and NYHA functional classifica-
ion were determined at each annual visit and included in
ome models as time-dependent co-variates. Atrial fibrilla-
ion and left bundle branch block were determined based on
nnual ECGs and were also handled in the models as
ime-dependent co-variates.
Nonfatal myocardial infarction—a primary outcome in
ERS—was diagnosed using an algorithm based on isch-
mic symptoms, ECG abnormalities, and elevated cardiac
nzymes levels (16). For this analysis, nonfatal myocardial
nfarction during the observation period was included as a
ime-dependent predictor for all-cause mortality.
Medication use determined at four-month intervals,
ased on participant self-reporting, was included in our
odels as a time-dependent co-variate. Once a medication
as initiated, we considered the participant a user of this
edication, even if it was subsequently discontinued; this
voids the potential bias that occurs because medications are
ften discontinued during the interval preceding death.
utcome. Death from any cause, determined by the inde-
endent morbidity and mortality committee after review of
eath certificates, was the outcome for this analysis. We
nvestigated the association between potential predictors
nd mortality that occurred during the combined HERS
nd HERS-II follow-up periods.
tatistical analysis. We used multivariable proportional
azards models to determine the association between cate-
ories of renal insufficiency and all-cause mortality. The
ollow-up time for women with incident HF after random-
zation was handled using left truncation until the time of
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revalent versus incident cases. Co-variates included in
hese models were baseline values for each risk factor, except
he number of myocardial infarctions, atrial fibrillation, left
undle branch block, and use of medications, which were
ncluded as time-dependent co-variates. We hypothesized
hat the association between renal insufficiency and mortal-
ty might vary by the presence of diabetes, hypertension,
ystolic dysfunction, or use of angiotensin-converting en-
yme (ACE) inhibitors, beta-blockers, calcium channel
lockers, or digoxin. We tested for interactions between
ategories of renal dysfunction, and these variables and
onsidered p  0.1 to indicate a statistically significant
nteraction.
We used penalized smooth splines to model the associ-
tion of creatinine clearance as a continuous (rather than
ategorical) predictor of mortality. We used backwards
election techniques to identify risk factors that were asso-
iated with mortality at p  0.1. We included medications
s time-dependent co-variates in all of the models, but did
ot interpret hazards associated with their use because of
oncern for confounding by indication. We repeated the
odels without adjustment for medications and verified
hat the associations were unchanged.
We estimated population-attributable risk (PAR) for
ach risk factor as (21):
PAR p · (RH 1) ⁄ (p · [RH 1])
here p is the prevalence of the risk factor at baseline and
H its adjusted hazard ratio (HR) from the multivariate
ox model for all-cause mortality. We used the baseline
revalence for each risk factor identified and the hazard
atio from the multivariate Cox model to estimate attribut-
ble risk for mortality.
Most analyses were performed in SAS version 8.2 (SAS
nstitute, Cary, North Carolina). The penalized spline fits
ere implemented in R (R Foundation for Statistical
omputing, Vienna, Austria).
ESULTS
f the 702 women with HF and coronary disease, 283 had
rCl 40 to 60 ml/min (40%) and 122 had CrCl40 (17%).
he mean serum creatinine values that corresponded to
ach of these categories was 1.0  0.2 mg/dl for CrCl 60
l/min, 1.2 0.2 mg/dl for CrCl 40 to 60 ml/min, and 1.6
0.5 mg/dl for CrCl40 ml/min. Those with more severe
enal dysfunction were older, more likely to have elevated
ystolic blood pressure, a history of coronary artery bypass
rafting, and a lower body mass index, more likely to be
aking diuretics and digoxin, and less likely to be taking
eta-blockers (Table 1).
During 5.8 1.7 years of average observation, 228 (32%)
f the 702 women died. Women with CrCl 60 ml/min
ad an annual mortality rate of 5% compared with 7.5% for
hose with CrCl 40 to 60 ml/min and 14% for those with
rCl 40 ml/min (p  0.001 for trend). We observed a Ctrong and graded association between the extent of renal
nsufficiency and mortality (Table 2). After adjusting for
emographic characteristics, co-morbid conditions, LVEF,
nd use of medications, women with CrCl40 ml/min had
more than twofold higher risk of death compared with
hose with CrCl 60 ml/min (adjusted HR 2.40, 95% CI
.60 to 3.62). Even women with CrCl 40 to 60 ml/min still
ad a 50% increased risk of death compared with those with
rCl 60 ml/min (adjusted HR 1.53, 95% CI 1.09 to
.16).
To confirm our a priori cutpoints for CrCl, we explored
he mortality risk associated with renal insufficiency for each
0-ml/min increment below a CrCl of 80 ml/min. The risk
f death appeared to increase at values 60 ml/min and
ccelerated upward below CrCl values40 ml/min (Fig. 1).
he HRs for each of these incremental decreases in CrCl
re presented in Table 3.
enal insufficiency and ventricular function. Of the 282
omen with HF and documented preserved systolic func-
ion, over half had renal insufficiency: 41% with CrCl 40 to
0 ml/min and 15% with CrCl 40 ml/min. Over one-half
f the 190 women with documented depressed systolic
unction had renal insufficiency: 35% with CrCl 40 to 60
l/min and 23% with CrCl 40 ml/min. The association
etween renal function and mortality did not differ by
reserved or depressed systolic function (for interaction: p
.38 for CrCl 40 to 60 ml/min, p  0.23 for CrCl 40
l/min).
enal insufficiency and ACE inhibition. We observed a
ifference in the association between renal insufficiency and
ortality among users and nonusers of ACE inhibitors.
omen with creatinine clearance 40 to 60 ml/min using
CE inhibitors had no increased risk of death, compared
ith those with CrCl 60 ml/min (adjusted HR 0.9, 95%
I 0.6 to 1.6) (Table 4). By contrast, women with CrCl 40
o 60 ml/min who did not use ACE inhibitors had a twofold
isk of death, compared with those with CrCl 60 ml/min
adjusted HR 2.1, 95% CI 1.3 to 3.2, p  0.02 for
nteraction). The risk of death also differed among users and
onusers of ACE inhibitors with CrCl 40 ml/min (ad-
usted HR 1.7, 95% CI 0.9 to 3.0 for ACE users vs. HR 3.1,
5% CI 1.8 to 5.0 for nonusers; p  0.1 for interaction).
We found no evidence that the risk of death associated
ith renal insufficiency varied by the presence of diabetes,
levated systolic blood pressure, or the use of beta-blockers,
alcium channel blockers, or digoxin.
ther risk factors associated with mortality. Using back-
ard selection techniques and the factors listed in Table 1,
e identified nine risk factors that were significantly asso-
iated with mortality on multivariate analysis (Table 5).
omen with symptoms of HF (defined as NYHA func-
ional class III or IV) had double the mortality risk
ompared with those with minimal symptoms; even NYHA
unctional class II conferred a small but significant increased
isk of mortality. Atrial fibrillation, diabetes, and depressed
rCl were also strongly associated with mortality. Multiple
m
r
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isk of death, but a single myocardial infarction was not.
ompared with women who had never smoked, current
mokers, but not former smokers, had an increased risk of
Table 1. Characteristics of 702 Women With
Renal Insufficiency
Demographic characteristics
Age (yrs, mean  SD)
Age 70 yrs
Race/ethnicity
Black
Other non-white race
Heart failure characteristics
New York Heart Association functional class
II
III/IV
Left ventricular ejection fraction
50%
Missing
Risk factors
Number of myocardial infarctions
1
1
Systolic blood pressure
100 mm Hg
140 mm Hg
Pulse 100 beats
Atrial fibrillation
Left bundle branch block
Left ventricular hypertrophy
History of coronary artery bypass grafting
History of percutaneous transluminal coronary
angiography
Diabetes on medication
Little or no exercise
Alcohol consumption
1–7 drinks/week
7 drinks/week
Smoking status
Former smoker
Current smoker
Body mass index
22 kg/m2
25–30 kg/m2
30 kg/m2
Serum sodium 137 mmol/l
Low-density lipoprotein cholesterol 130 mg/dl
High-density lipoprotein cholesterol 35 mg/dl
Triglycerides 200 mg/dl
Lipoprotein (a) 25.3 mg/dl
Angiotensin-converting enzyme inhibitor use
Beta-blocker use
Calcium channel blocker use
Digoxin use
Diuretic use
Statin use
Aspirin use
CrCl  creatinine clearance.eath. Age over 70 years, depressed systolic function, and aimited exercise were also independently associated with an
ncreased risk of death.
opulation-attributable risk. Of the risk factors listed in
able 5, renal insufficiency had the greatest population-
t Failure and Coronary Disease by Degree of
CrCl
p Value
for Trend
ml/min
297)
40–60 ml/min
(n  283)
<40 ml/min
(n  122)
 6 70  6 72  5 0.001
0 52 75 0.001
3 10 12 0.4
5 4 3
1 12 15 0.1
1 2 7
2 41 34 0.7
1 36 31
9 48 53 0.2
9 11 12
2 1 2 0.003
2 47 44
0.3 0.7 0.8 0.5
2 2 5 0.1
1 11 16 0.2
3 15 14 0.6
0 48 53 0.008
3 35 34 0.03
7 29 32 0.1
3 29 41 0.1
3 26 26 0.5
3 3 2
0 50 48 0.09
5 13 9
1 7 16 0.001
9 40 42
5 28 16
4 4 5 0.8
6 62 62 0.4
2 11 14 0.8
2 29 36 0.7
3 54 51 0.8
0 44 48 0.1
4 40 30 0.009
1 65 71 0.04
4 29 35 0.02
3 64 72 0.005
2 45 40 0.9
1 79 75 0.2Hear
>60
(n 
64
2
1
1
4
3
4
3
1
1
4
4
3
4
2
5
1
2
6
6
1
3
5
4
4
6
2
6
4
8ttributable risk for mortality (27%) (Fig. 2). By contrast,
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October 19, 2004:1593–600 Renal Insufficiency Among Women With HFtrial fibrillation, NYHA functional class III/IV, and more
han one myocardial infarction were each responsible for
5% attributable risk. An LVEF was included in the model
o estimate adjusted HRs, but population-attributable risk
as not calculated for LVEF because of the missing values.
ISCUSSION
e found that renal insufficiency, even when mild, was
ndependently associated with mortality among women
ith HF and coronary disease. This association between
enal insufficiency and mortality was independent of diabe-
es, hypertension, and other risk factors for mortality and
id not vary by the presence of preserved or depressed
ystolic function. There appeared to be no increased risk of
ortality among women with mild renal insufficiency (CrCl
0 to 60 ml/min) who were using ACE inhibitors. We
dentified eight other independent risk factors for mortality
mong women with HF and coronary disease. Of these
actors, renal insufficiency was the most common and was
ssociated with the greatest population-attributable risk for
ortality. These results highlight the importance of renal
nsufficiency as a prevalent and potent risk factor for death
mong women with HF, even among those with preserved
ystolic function, and raises the hypothesis that this risk
ould be modified by appropriate medical therapy.
able 2. Mortality Associated With Renal Insufficiency Among W
Deaths/N*
Unadjusted
HR (95% CI)
Adjusted H
Demogra
Characteri
(95% C
rCl
60 ml/min 69/297 1.0 1.0
40–60 ml/min 94/283 1.54 (1.13–2.11) 1.53 (1.10–
40 ml/min 65/122 2.91 (2.07–4.11) 2.82 (1.90–
Number dead during observation period/total number in category. †Adjusted for age i
140 mm Hg and number of myocardial infarctions (last variable included as a time
140 mm Hg, number of myocardial infarctions, and left ventricular ejection fraction
umber of myocardial infarctions, LVEF, and use of angiotensin-converting enzyme
medications included as time-dependent co-variates).
CI  confidence interval; CrCl  creatinine clearance; HR  hazard ratio.bigure 1. Risk of death associated with level of creatinine clearance among
omen with heart failure and coronary disease.An increased risk of mortality among persons with mild
o moderate renal insufficiency has previously been observed
redominantly among individuals with HF with depressed
ystolic function (5–7,10,11,22), and many of these studies
ncluded only small numbers of women (6,7,10). Several
echanisms have been proposed to explain this increased
ortality risk, including the possibilities that renal insuffi-
iency is a marker for more severe HF, is associated with a
igher burden of co-morbid illness such as diabetes, and
ay limit the use of effective HF medications, especially
CE inhibitors. In our analysis, we adjusted for HF severity
nd co-morbid illnesses and still observed an independent
ssociation between mild renal insufficiency and mortality.
dditionally, in contrast to previous studies, we accounted
or multiple medications used over the entire observation
eriod and still observe the association of renal insufficiency
ith mortality, suggesting that these proposed mechanisms
hus proposed are unlikely. Alternative explanations include
he possibility that renal insufficiency may accelerate the
rogression of HF and thus increase the risk of mortality or
hat renal insufficiency may be a marker for the same
nderlying process causing mortality from HF (e.g., ad-
anced microvascular disease). More animal and human
tudies are needed to determine the nature of the relation-
hip between renal insufficiency and HF, and additional
nvestigations should also focus on whether stabilization of
able 3. Risk of Death Associated With 10-ml/min Increment
ecreases of Creatinine Clearance Among Women With Heart
ailure and Coronary Disease
n (%)
Adjusted HR*
(95% CI) p Value
rCl (ml/min)
80 118 (17) 1.0 —
71–80 76 (11) 0.9 (0.5–1.8) 0.8
61–70 103 (15) 1.0 (0.6–1.8) 0.9
51–60 144 (20) 1.5 (0.9–2.4) 0.1
41–50 139 (20) 1.6 (1.0–2.7) 0.05
31–40 91 (13) 2.0 (1.2–3.4) 0.01
30 31 (4) 4.7 (2.5–8.8) 0.001
Adjusted for age, race/ethnicity, diabetes, systolic blood pressure 140 mm Hg,
umber of myocardial infarctions, left ventricular ejection fraction, and use of
en With Heart Failure and Coronary Disease
r
Plus Comorbid
Conditions‡
HR (95% CI)
Plus LVEF§
HR (95% CI)
Plus Medications¶
HR (95% CI)
1.0 1.0 1.0
1.58 (1.13–2.22) 1.60 (1.14–2.25) 1.53 (1.09–2.16)
2.67 (1.79–3.98) 2.57 (1.72–3.84) 2.40 (1.60–3.62)
and race/ethnicity. ‡Adjusted for age, race/ethnicity, diabetes, systolic blood pressure
dent co-variate). §Adjusted for age, race/ethnicity, diabetes, systolic blood pressure
F). ¶Adjusted for age, race/ethnicity, diabetes, systolic blood pressure 140 mm Hg,
itors, beta-blockers, aspirin, calcium channel blockers, diuretics, digoxin, and statinsom
R fo
phic
stics†
I)
2.15)
4.18)
n years
-depen
(LVE
inhibeta-blockers, aspirin, calcium channel blockers, diuretics, digoxin, and statins.
Abbreviations as in Table 2.
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Renal Insufficiency Among Women With HF October 19, 2004:1593–600enal insufficiency may be associated with improved HF
ortality.
Our study offers preliminary evidence for the beneficial
ffect of ACE inhibitors on mortality in the setting of mild
o moderate renal insufficiency. Women with mild to
oderate renal impairment (CrCl 40 to 60 ml/min) who
sed ACE inhibitors had a similar mortality risk to women
ith CrCl 60 ml/min. Currently, guidance for clinicians
aring for patients who have HF and renal insufficiency is
acking, as no clinical trials have focused on treatment of
hese patients, and persons with renal insufficiency are
oorly represented in clinical trials (23). More research in
his high-risk population is needed, particularly to guide the
osing and administration of potentially beneficial medica-
ions like ACE inhibitors and other treatments, including
ngiotensin receptor blockers and spironolactone, as renal
nsufficiency worsens.
Our study included women with both preserved and
epressed systolic function, and we found renal insufficiency
o predict mortality independent of systolic function. Heart
ailure with preserved systolic function is known to be a
Table 4. Association Between Renal Insufficien
Angiotensin-Converting Enzyme Inhibitors
ACE Inhibitors (n 
n
Adjusted HR§
(95% CI)
CrCl
60 ml/min 183 1.0
40–60 ml/min* 189 0.9 (0.6–1.6)
40 ml/min† 88 1.7 (0.9–3.0)
*p for interaction  0.02 for creatinine clearance 40–60 ml/
ACE inhibitor use defined as time-dependent co-variate. Pa
users. §Adjusted for age, race/ethnicity, diabetes, systolic blo
ventricular ejection fraction, and use of beta-blockers, aspirin
ACE  angiotensin-converting enzyme; other abbreviati
Table 5. Adjusted Hazard Ratios Associated W
Women With Heart Failure and Coronary Di
NYHA functional class† (vs. class 0 or 1)
II
III/IV
Atrial fibrillation†
Diabetes
CrCl 60 ml/min
Number of myocardial infarctions†
(vs. no myocardial infarctions)
1
1
Smoking (vs. never smoked)
Former smoker
Current smoker
Age 70 yrs
Left ventricular ejection fraction 50%
Little or no exercise
*Also adjusted for medications, race (African-American vs. w
block (HR 1.3, 95% CI 1.0–1.8, p  0.07). †These variables
(%) represents values at baseline for each variable.
NYHA  New York Heart Association; other abbreviations asore common presentation of HF in women (14). Cur-
ently, there are few clinical trials completed that evaluated
he appropriate management of patients with HF and
reserved systolic function (24). Future clinical trials of the
reatment for HF with preserved systolic function should
onsider the prognostic importance of renal insufficiency
nd investigate the effectiveness of treatment strategies as
enal insufficiency worsens.
We identified several other risk factors for mortality
mong these women with HF and coronary disease. The
trong association between functional limitations due to HF
ymptoms and all-cause mortality highlights HF as a
rogressive symptomatic disorder in which patients often
ove through worsening stages of symptoms to death. Like
thers, we observed that the association between NYHA
unctional class and death is independent of systolic func-
ion (25–27); this observation is of particular importance in
he management of women with HF because of the high
revalence of preserved systolic function. More study is
ecessary to determine the natural history of HF with
reserved LVEF, the progression of symptoms, and the
nd Mortality, Stratified by Use of
No ACE Inhibitors (n  242)
alue n
Adjusted HR§
(95% CI) p Value
— 114 1.0 —
0.8 94 2.1 (1.3–3.2) 0.001
0.1 34 3.1 (1.8–5.0) 0.001
For interaction  0.1 for creatinine clearance 40 ml/min.
nts who subsequently discontinued ACE use are defined as
ssure 140 mm Hg, number of myocardial infarctions, left
ium channel blockers, diuretics, digoxin, and statins.
in Table 2.
Risk Factors for All-Cause Mortality Among
%)
Adjusted HR*
(95% CI) p Value
(12) 1.6 (1.1–2.4) 0.03
(3) 2.0 (1.1–3.8) 0.03
(3) 1.9 (1.2–3.1) 0.006
(33) 1.8 (1.3–2.4) 0.001
(58) 1.6 (1.2–2.2) 0.003
(49) 0.9 (0.6–1.2) 0.35
(8) 1.6 (1.1–2.3) 0.02
1.0 (0.7–1.3) 0.90
(13) 1.6 (1.1–2.5) 0.02
(42) 1.5 (1.1–2.0) 0.009
(27) 1.5 (1.1–2.2) 0.02
(37) 1.3 (1.0–1.8) 0.04
R 0.9, 95% CI 0.6–1.4, p  0.78), and left bundle branch
luded in the model as time-varying co-variates. The numbercy a
460)
p V
min. †
rticipa
od preith
sease
n (
83
18
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230
405
346
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94
299
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262
hite, H
are incin Table 2.
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omes. The identification of decreased functional status is
mportant among all patients, especially the elderly. Among
atients with depressed LVEF, the identification of de-
reased functional status due to HF symptoms is crucial,
ecause it should prompt the initiation of pharmacologic
nd perhaps nonpharmacologic therapies that have been
hown to improve prognosis in symptomatic women.
Clinicians caring for women with HF must pay particular
ttention to the progression of renal insufficiency, as this is
common risk factor that carries important prognostic
ignificance. Assessment of functional status is also crucial
or both for guiding therapies as well as educating patients
bout the progressive nature of this disease. In addition to
he initiation of appropriate pharmacotherapy, modifiable
isk factors such as tobacco use and limited exercise should
e addressed. A meta-analysis of several small trials suggests
hat exercise training programs can reduce mortality among
atients with HF (28). Our study supports the possibility of
imited exercise as an independent (and potentially modifi-
ble) risk factor, because we observe this association inde-
endent of HF symptoms.
One limitation of this analysis is that our study was
omposed of women who were voluntary participants in a
linical trial. The entry criteria in HERS excluded women
ho were severely infirm, which likely represented the
omen most symptomatic with HF who would have had
he greatest mortality risk. Additionally, clinical trial par-
icipants are likely to be healthier and more health conscious
han typical community-dwelling women with HF. As a
igure 2. Population-attributable risk associated with risk factors for morta
eart Association.esult of these differences, the associations that we detectedere could be somewhat biased and the attributable risk may
e different in other populations. An additional limitation is
hat the assessment of LVEF was based on chart review at
aseline, the measures of LVEF were not standardized, and
significant percentage was missing.
onclusions. Renal insufficiency is a common and power-
ul predictor of mortality among women with HF. The
mportant prognostic implications of renal insufficiency
mong women with HF and the dearth of information on
he pathophysiology and clinical management of patients
ith both cardiac and renal insufficiency suggest fertile
round for future research that could lead to reductions in
ortality from these common and deadly diseases.
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